

## Plain English Summary

# Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer

## What does the guidance say?

Osimertinib is recommended for listing on the Medication Assistance Fund (MAF) for government funding for patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer who meet certain criteria.

## What is non-small-cell lung cancer (NSCLC)?

Lung cancer occurs when abnormal cells grow uncontrollably in one or both of the lungs. Doctors classify lung cancer into different subtypes depending on the type of cells in the lung that are affected. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Common symptoms of lung cancer include coughing, chest pain and trouble breathing.

When the cancer spreads to both lungs or to other parts of the body, this is known as advanced or metastatic disease.

## What is an epidermal growth factor receptor (EGFR) mutation?

The EGFR gene helps cells grow and divide. Some patients with NSCLC have a mutation in the EGFR gene which causes abnormal cell growth. This is known as EGFR mutation-positive NSCLC. EGFR mutations are common in Asian populations.

At least 50% of patients with EGFR mutation-positive NSCLC can also develop a T790M mutation in the EGFR gene which causes certain treatments to stop working (resistance).

Doctors test patients with lung cancer to see if they have any mutations so they can determine which treatments are likely to work best.

## What is osimertinib?

Osimertinib belongs to a group of medicines called tyrosine kinase inhibitors (TKIs) which can stop cells from growing and dividing and can prevent cancer from spreading. It is given to patients with NSCLC who have a T790M mutation in the EGFR gene that causes other types of TKIs to not work properly.

Osimertinib is taken orally. Your doctor will tell you how long you need to take it for.

## Plain English Summary

# Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer

## Who can have osimertinib?

Adults with non-small-cell lung cancer can have osimertinib if they have a T790M mutation in the EGFR gene confirmed by a diagnostic test, and the cancer:

- has spread to both lungs or to other organs; and
- has continued to worsen despite previous treatment with other TKI therapy.

Your doctor can advise if osimertinib is a suitable treatment for you.

## Why was osimertinib recommended for funding?

ACE evaluates how well a treatment works in relation to how much it costs compared to other treatments. Osimertinib was recommended for funding because its benefit in improving survival for certain patients with advanced EGFR T790M mutation-positive NSCLC justifies its cost compared to other treatments.

## What does listing on MAF mean for me?

The MAF helps people pay for expensive treatments that are clinically necessary. If your doctor prescribes osimertinib for you, and you meet the MAF criteria, your treatment cost will be subsidised by 40% to 75%.

Osimertinib has also been included on the Cancer Drug List (CDL) and is claimable under MediShield Life. The subsidy class and MediShield Life claim limits are available at [go.gov.sg/moh-cancer-drug-list](http://go.gov.sg/moh-cancer-drug-list).

**Published: 12 July 2022**

 Agency for Care Effectiveness - ACE

 Agency for Care Effectiveness (ACE)

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education. It publishes guidances on diagnosing, treating, and preventing different medical conditions based on the latest research information available worldwide.

This summary is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition.

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore  
All rights reserved. Reproduction of this publication in whole or part in any material form is prohibited without the prior written permission of the copyright holder.

To find out more about ACE visit [www.ace-hta.gov.sg](http://www.ace-hta.gov.sg)